“Poorly differentiated” refers to cancer cells that have more abnormalities and look less like normal cancer cells. Poorly differentiated thyroid cancer is uncommon, accounting for fewer than 5% of ...

Papillary and follicular thyroid cancers are considered well-differentiated cancers. Papillary thyroid cancer is the most prevalent type of thyroid cancer--with over 50,000 new cases per year in the ...

Thyroid cancer recurrence risk was not elevated among patients with high-normal vs low-normal exposure to TSH following thyroidectomy.

If a doctor has diagnosed you with thyroid cancer, the next step in your cancer journey may be treatment. What are your treatment options, and how do doctors decide which one might be best for you?

A 5-year follow-up of those randomized to receive or not receive radioiodine after thyroidectomy showed nearly the same low ...

Well differentiated thyroid cancers can be further categorized as papillary thyroid cancer (the most common) and follicular thyroid cancer. Well differentiated thyroid cancers have an excellent ...

More information: Thi-Van-Trinh Tran et al, All-Cause and Cause-Specific Mortality Among Low-Risk Differentiated Thyroid Cancer Survivors in the United States, Thyroid (2023). DOI: 10.1089/thy ...

Treatment of thyroid nodules and differentiated thyroid cancer can generally be safely postponed until after delivery. As diagnosing thyroid diseases during pregnancy may be difficult, adequate ...

Introduction: Radioactive iodine (RAI) has been utilized for nearly 80 years in treating both hyperthyroidism and thyroid cancer, and it continues to play a central role in the management of ...

The hypothalamic–pituitary–thyroid axis plays a crucial role in the pathogenesis, diagnosis, risk stratification, effectiveness of radioiodine therapy, and treatment response evaluation in epithelial ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

A phase 2 trial found that dual immune checkpoint inhibition with nivolumab and ipilimumab shows promise in anaplastic thyroid cancer, but limited effectiveness in radioiodine refractory ...